NO20065487L - Modulering av immunglobulinproduksjon og atopiske forstyrrelser - Google Patents

Modulering av immunglobulinproduksjon og atopiske forstyrrelser

Info

Publication number
NO20065487L
NO20065487L NO20065487A NO20065487A NO20065487L NO 20065487 L NO20065487 L NO 20065487L NO 20065487 A NO20065487 A NO 20065487A NO 20065487 A NO20065487 A NO 20065487A NO 20065487 L NO20065487 L NO 20065487L
Authority
NO
Norway
Prior art keywords
modulation
immunoglobulin production
atopic disorders
disorders
atopic
Prior art date
Application number
NO20065487A
Other languages
English (en)
Norwegian (no)
Inventor
Mary Collins
Marion Kasaian
Nancy L Wood
Debra D Donaldson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20065487L publication Critical patent/NO20065487L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20065487A 2004-05-19 2006-11-28 Modulering av immunglobulinproduksjon og atopiske forstyrrelser NO20065487L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57240704P 2004-05-19 2004-05-19
PCT/US2005/017514 WO2005112983A2 (en) 2004-05-19 2005-05-19 Modulation of immunoglobulin production and atopic disorders

Publications (1)

Publication Number Publication Date
NO20065487L true NO20065487L (no) 2006-12-18

Family

ID=35428852

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065487A NO20065487L (no) 2004-05-19 2006-11-28 Modulering av immunglobulinproduksjon og atopiske forstyrrelser

Country Status (15)

Country Link
US (1) US20060024268A1 (zh)
EP (1) EP1753458A4 (zh)
JP (1) JP2008501042A (zh)
KR (1) KR20070014181A (zh)
CN (1) CN1980698A (zh)
AU (1) AU2005244942A1 (zh)
BR (1) BRPI0510996A (zh)
CA (1) CA2566333A1 (zh)
EC (1) ECSP067014A (zh)
IL (1) IL179243A0 (zh)
MX (1) MXPA06013483A (zh)
NO (1) NO20065487L (zh)
RU (1) RU2006138704A (zh)
WO (1) WO2005112983A2 (zh)
ZA (1) ZA200609600B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
EP1553982A4 (en) 2002-07-15 2008-03-26 Wyeth Corp METHOD AND COMPOSITIONS FOR MODULATING THE DEVELOPMENT AND FUNCTION OF T-HELPER CELLS (T sb H / sb)
MXPA05009556A (es) 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
ZA200507235B (en) * 2003-03-21 2007-03-28 Wyeth Corp Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor
CA2538083A1 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
EP2641611A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
JP2008508885A (ja) * 2004-08-05 2008-03-27 ワイス インターロイキン−２１受容体活性を中和すること
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
DE602006020032D1 (de) * 2005-04-18 2011-03-24 Novo Nordisk As Il-21-varianten
RU2420308C2 (ru) * 2005-06-06 2011-06-10 Ново Нордикс А/С Стабилизированные композиции ил-21
US7914574B2 (en) * 2005-08-02 2011-03-29 Reva Medical, Inc. Axially nested slide and lock expandable device
WO2007114861A2 (en) * 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
AU2006340750B2 (en) 2005-11-28 2013-03-07 Zymogenetics, Inc. IL-21 antagonists
CA2666426A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
EP2109620B1 (en) * 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
WO2010055366A2 (en) 2007-12-07 2010-05-20 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
AR072136A1 (es) * 2008-05-23 2010-08-11 Wyeth Corp Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21
AR071885A1 (es) * 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
JP2012504939A (ja) * 2008-09-23 2012-03-01 ワイス・エルエルシー 架橋結合タンパク質による活性化シグナルの産生を予測するための方法
WO2010119307A1 (en) * 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells
RS60050B1 (sr) 2011-01-18 2020-04-30 Bioniz Llc Kompozicije za modulaciju aktivnosti gama-c-citokina
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
CA2915882C (en) 2013-06-27 2022-12-06 Monash University Il-21 binding proteins and uses thereof
AU2015367224B2 (en) 2014-12-19 2020-12-10 Monash University IL-21 antibodies
ES2884357T3 (es) 2015-10-09 2021-12-10 Bioniz Llc Modulación de la actividad de las citocinas gamma-c
US11709169B2 (en) * 2017-02-07 2023-07-25 National Jewish Health Lipid abnormalities and association with atopic allergic diseases
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO1990013327A1 (en) * 1989-04-28 1990-11-15 Riker Laboratories, Inc. Dry powder inhalation device
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
SE9502800D0 (sv) * 1995-08-10 1995-08-10 Astra Ab Disposable inhaler
US20030143204A1 (en) * 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
US6777539B2 (en) * 2000-04-05 2004-08-17 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
CA2312142A1 (en) * 2000-06-22 2001-12-22 An-Go-Gen Inc. Injection system for gene delivery
DK1451322T3 (da) * 2001-11-05 2010-02-01 Zymogenetics Inc Il-21-antagonister
WO2003064621A2 (en) * 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US7556944B2 (en) * 2002-05-03 2009-07-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing siRNAs
WO2004015062A2 (en) * 2002-08-12 2004-02-19 New England Biolabs, Inc. Methods and compositions relating to gene silencing
PL376118A1 (en) * 2002-10-11 2005-12-12 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
ZA200507235B (en) * 2003-03-21 2007-03-28 Wyeth Corp Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis

Also Published As

Publication number Publication date
KR20070014181A (ko) 2007-01-31
ECSP067014A (es) 2006-12-29
IL179243A0 (en) 2007-03-08
BRPI0510996A (pt) 2007-12-04
RU2006138704A (ru) 2008-06-27
AU2005244942A1 (en) 2005-12-01
MXPA06013483A (es) 2007-01-23
ZA200609600B (en) 2010-04-28
JP2008501042A (ja) 2008-01-17
EP1753458A2 (en) 2007-02-21
US20060024268A1 (en) 2006-02-02
WO2005112983A3 (en) 2006-10-05
CN1980698A (zh) 2007-06-13
EP1753458A4 (en) 2009-07-22
CA2566333A1 (en) 2005-12-01
WO2005112983A2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
NO20065487L (no) Modulering av immunglobulinproduksjon og atopiske forstyrrelser
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
NO20070189L (no) Immunoglobuliner
NO20052591L (no) Pyridopyrolizin og pyridoindolizinderivater
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2005063820A3 (en) Il-7 fusion proteins
WO2018151821A8 (en) ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF
EP4285923A3 (en) Antibody molecules to april and uses thereof
AU2018282094A1 (en) Antibodies that specifically bind PD-1 and methods of use
MX2009010765A (es) Anticuerpos anti-ige.
MY147217A (en) Antibody molecules having specificity for human il-06
WO2007141533A3 (en) Fkbp-l and uses thereof
TW200736274A (en) Immunoglobulins
WO2007001264A3 (en) Method of making recombinant human antibodies for use in biosensor technology
WO2005056759A3 (en) Methods of generating variant proteins with increased host string content and compositions thereof
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
NO20082942L (no) Ligander som binder IL-4 og/eller IL-13
WO2009052081A3 (en) Antibodies that bind il-4 and/or il-13 and their uses
WO2006122187A3 (en) Treating and evaluating inflammatory disorders
AU2016219704A1 (en) Anti-Notch1 antibodies
MX347978B (es) Uso de los anticuerpos anti-il-17a y anti-il-17f en el tratamiento de la resistentes a insulina.
DK1407276T3 (da) Anvendelse af hypoxia-inducerbar faktor 2-alfa til helbredelse af neonatalt respiratory distress syndrom
WO2021146320A8 (en) Antibody molecules to c5ar1 and uses thereof
PH12018501739A1 (en) Antibodies for il-17c
MX2021008621A (es) Anticuerpos de inmunoglobulina a y metodos de produccion y uso.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application